Ralf Buettner

7.6k total citations · 2 hit papers
63 papers, 5.6k citations indexed

About

Ralf Buettner is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Ralf Buettner has authored 63 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 22 papers in Molecular Biology and 13 papers in Hematology. Recurrent topics in Ralf Buettner's work include Cytokine Signaling Pathways and Interactions (24 papers), Cancer Mechanisms and Therapy (11 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Ralf Buettner is often cited by papers focused on Cytokine Signaling Pathways and Interactions (24 papers), Cancer Mechanisms and Therapy (11 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Ralf Buettner collaborates with scholars based in United States, Germany and India. Ralf Buettner's co-authors include Richard Jove, Hua Yu, Linda Mora, Andreas Herrmann, Heehyoung Lee, Sangkil Nam, Jin Cheng, Steve Enkemann, Janni Mirosevich and Adina Vultur and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature reviews. Cancer and Blood.

In The Last Decade

Ralf Buettner

60 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revisiting STAT3 signalling in cancer: new and unexpected biological functions

2014 1.7k citations Hua Yu, Andreas Herrmann et al. profile →
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

2002 893 citations Ralf Buettner, Richard Jove et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ralf Buettner United States	24	2.9k	2.9k	1.1k	1.1k	834	63	5.6k
Guilian Niu United States	16	3.6k 1.2×	2.6k 0.9×	2.0k 1.8×	1.1k 1.1×	878 1.1×	19	5.7k
Tammy Bowman United States	16	3.9k 1.3×	2.9k 1.0×	1.1k 1.0×	894 0.8×	1.1k 1.3×	19	5.4k
Hiroko Oshima Japan	40	2.2k 0.7×	4.0k 1.4×	1.1k 1.0×	1.7k 1.6×	876 1.1×	87	8.2k
Lanxi Song United States	20	2.1k 0.7×	2.2k 0.8×	615 0.5×	664 0.6×	517 0.6×	23	3.9k
James G. Karras United States	33	2.6k 0.9×	2.5k 0.8×	1.9k 1.7×	945 0.9×	953 1.1×	57	5.6k
Jiayuh Lin United States	55	5.3k 1.8×	4.9k 1.7×	1.2k 1.0×	1.3k 1.2×	1.3k 1.6×	137	8.6k
Fengzhi Li United States	45	3.2k 1.1×	6.9k 2.4×	1.5k 1.3×	1.1k 1.0×	445 0.5×	139	9.1k
Franca Stivala Italy	28	1.6k 0.5×	3.5k 1.2×	528 0.5×	868 0.8×	653 0.8×	58	5.4k
Jennifer R. Grandis United States	29	2.8k 1.0×	2.2k 0.7×	615 0.5×	813 0.8×	691 0.8×	42	4.3k
Kuen‐Feng Chen Taiwan	43	1.6k 0.5×	3.1k 1.1×	560 0.5×	975 0.9×	679 0.8×	100	4.9k

Countries citing papers authored by Ralf Buettner

Since Specialization

Citations

This map shows the geographic impact of Ralf Buettner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf Buettner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf Buettner more than expected).

Fields of papers citing papers by Ralf Buettner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralf Buettner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf Buettner. The network helps show where Ralf Buettner may publish in the future.

Co-authorship network of co-authors of Ralf Buettner

This figure shows the co-authorship network connecting the top 25 collaborators of Ralf Buettner. A scholar is included among the top collaborators of Ralf Buettner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf Buettner. Ralf Buettner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Pullarkat, Vinod, Lisa S. Chen, Joycelynne Palmer, et al.. (2023). A phase 1 trial of 8‐chloro‐adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics. Cancer. 130(5). 727–739. 2 indexed citations

2.

Buettner, Ralf, Le Xuan Truong Nguyen, Xiwei Wu, et al.. (2021). Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. Journal of Hematology & Oncology. 14(1). 70–70. 41 indexed citations

3.

Buettner, Ralf, Xiwei Wu, James F. Sanchez, et al.. (2019). Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting. Molecular Therapy — Oncolytics. 14. 149–158. 21 indexed citations

4.

Wen, Wei, Ernest Han, Thanh H. Dellinger, et al.. (2019). Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer. Translational Oncology. 12(8). 1015–1025. 9 indexed citations

5.

Buettner, Ralf, Enrico Caserta, Domenico Viola, et al.. (2017). Leflunomide Inhibits c-Myc Signaling and Impairs Myeloma Cell Growth. Blood. 130. 4426–4426. 2 indexed citations

6.

Rosenzweig, Michael, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2017). Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial. Blood. 130. 3144–3144.

7.

Namanja, Andrew T., et al.. (2016). Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation. Journal of Molecular Biology. 428(3). 579–589. 21 indexed citations

8.

Ara, Tasnim, Rie Nakata, Michael A. Sheard, et al.. (2013). Critical Role of STAT3 in IL-6–Mediated Drug Resistance in Human Neuroblastoma. Cancer Research. 73(13). 3852–3864. 105 indexed citations

9.

Schroeder, Anne, Andreas Herrmann, Gregory Cherryholmes, et al.. (2013). Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling. Cancer Research. 74(4). 1227–1237. 156 indexed citations

10.

Li, Min‐Yi, Yan Tian, Li Shen, et al.. (2013). 3-O-methylthespesilactam, a new small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells. Biochemical Pharmacology. 86(10). 1411–1418. 12 indexed citations

11.

Yang, Fan, Veronica Jové, Ralf Buettner, et al.. (2012). Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biology & Therapy. 13(6). 349–357. 27 indexed citations

12.

Liu, Lucy, Marina Kritsanida, Prokopios Magiatis, et al.. (2012). A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling. Cancer Biology & Therapy. 13(13). 1255–1261. 30 indexed citations

13.

Yang, Fan, Veronica Jové, Ralf Buettner, et al.. (2012). Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biology & Therapy. 13(7). 534–541. 23 indexed citations

14.

Buettner, Ralf, Stefan Farkas, Axel Holstege, et al.. (2010). Giant Cell Hepatitis: an Unusual Cause of Fulminant Liver Failure. Zeitschrift für Gastroenterologie. 48(11). 1293–1296. 6 indexed citations

15.

Lin, Jianping, Ralf Buettner, Yate‐Ching Yuan, et al.. (2009). Molecular dynamics simulations of the conformational changes in signal transducers and activators of transcription, Stat1 and Stat3. Journal of Molecular Graphics and Modelling. 28(4). 347–356. 22 indexed citations

16.

Vultur, Adina, et al.. (2007). SKI-606, a novel Src kinase inhibitor, blocks migration and invasion of human breast cancer cells. Cancer Research. 67. 3251–3251. 1 indexed citations

17.

Buettner, Ralf, Tania Mesa, Sangkil Nam, Frank Lee, & Richard Jove. (2007). The Src family kinase inhibitor dasatinib (BMS-354825) blocks migration and invasion of human melanoma cells. Cancer Research. 67. 3248–3248. 1 indexed citations

18.

Nam, Sangkil, Donghwa Kim, Jin Cheng, et al.. (2006). Dasatinib (BMS-354825), a novel multi-targeted kinase inhibitor that blocks tumor cell migration and invasion, is a promising therapeutic agent for metastatic prostate cancer. Cancer Research. 66. 893–893. 2 indexed citations

19.

Buettner, Ralf, Mei Huang, Greg Bloom, et al.. (2004). Novel Stat3-regulated genes in prostate cancer identified by microarray analysis.. Cancer Research. 64. 556–556. 1 indexed citations

20.

Smith, Claire M., et al.. (1996). 5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro.. The Journal of Clinical Endocrinology & Metabolism. 81(4). 1361–1366. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact